Entera Bio Ltd. stock is up 55.17% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 5 March’s closed higher than February.
Entera Bio Ltd. focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!